| 标题 |
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial
|
| 备注 |
不是补充材料
💡 该求助存在备注,如果存在信息冲突,请以备注为准
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 |
期刊:Journal of Clinical Oncology 作者:A. Thiery-Vuillemin; F. Saad; Andrew J. Armstrong; M. Oya; K. Vianna; et al 出版日期:2023-06-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)